Traditional Chinese medicine classic herbal formula Xiaoqinglong decoction for acute exacerbation of chronic obstructive pulmonary disease: A systematic review protocol.

BACKGROUND: Xiaoqinglong decoction (XQLD) is 1 of the traditional Chinese medicine (TCM) classic herbal formula that is widely used in Asian for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). In recent years, there has been increasing interest in the use of XQLD to treat COPD in China. So it is necessary to update the research and re-evaluate the efficacy and safety of XQLD to provide up-to-date evidence for COPD management. Therefore, we provide a protocol for a systematic review of XQLD for COPD. This protocol is described for a systematic review to investigate the beneficial effects and safety of XQLD for AECOPD. METHODS: A systematic literature search for article up to October 2018 will be performed in 3 Chinese electronic databases and 2 English electronic databases: Pubmed, Cochrane library, China national knowledge infrastructure (CNKI), Chinese science and technology periodical database (VIP), and Wanfang database. Inclusion criteria are randomized control trials of XQLD in treating AECOPD. The primary outcomes were total clinical efficacy rate, TCM symptom scores, TCM Symptom relief time. The secondary outcome was lung function, blood gas analysis, inflammatory cytokines and C-reactive protein (CRP). The summary results will be pooled using the random-effects model or fixed-effects model according to the heterogeneity of the included studies. RESULT: This systematic review will provide an evidence of XQLD for AECOPD, and will submit to a peer-reviewed journal for publication. CONCLUSION: The conclusion of this systematic review will provide evidence to judge whether XQLD is an effective intervention for AECOPD patients.

Effect of Yiqigubiao Pill Regulate Inflammatory Cytokines Through JAK/STAT Pathway in COPD Rats Model / 世界科学技术-中医药现代化

The research observed the effect of Yiqigubiao Pill regulating inflammatory reaction mRNA expression in JAK/STAT pathway in COPD rats model and explored protective effect of Yiqigubiao pills in the treatment or auxiliary possible mechanism in COPD. 60 SFP Wistar rats were divided randomly into control group (CN), COPD model group (M) and Yiqigubiao Pill group (Yqgb). The rats in group M and group YQGB were establish by using the method of LPS and smoking as COPD, rats in group M and group CN were given normal saline intragastric administration, and rats in the YQGB group were given water solution intragastric administration at the corresponding dose, twice a day. After using drugs for 12 weeks, we used ELISA method to detect changes inIL-17a, IL-23, IFN-γ and RORγt expression in peripheral blood, RT-PCR method to detect changes in the expression of JAK1, JAK3, STAT1 and STAT3 mRNA in lung tissues. Compared with the group CN, the infiltration of inflammatory cells stained by HE in the experimental group was reduced, and the diameter of the bronchial lumen was broadened (P ＜ 0.01). Both of ELISA and RT-PCR results showed that, compared with group CN, the levels of IL-17a, IL-23 and RORγt, the levels of JAK1, JAK3, STAT1, and STAT3 mRNA were increased in group M. Compared with group M, the mRNA levels of above indicators in group Yqgb were decreased, and the difference was statistically significant (P ＜ 0.01). Correlation analysis revealed that JAK1, JAK3, STAT1 and STAT3 were associated with IL-17a, IL-23, and RORγt had statistical significance (P ＜ 0.05). Therefore, Yiqgubiao Pill can inhibit the inflammatory response in COPD rats model, and its mechanism may be associated with inhibition of JAK/STAT pathway.

Effect of Abnormal Savda Munziq, a Traditional Uighur Herbal Medicine, on Pulmonary Function and Aquaporins of COPD Rat Model with Abnormal Savda Syndrome.

OBJECTIVE: To investigate the effect of abnormal savda munziq (ASM) on the pulmonary function and expression of lung-specific aquaporins in the rat model of chronic obstructive pulmonary disease with abnormal savda syndrome (ASSCOPD). METHODS: Eighty male rats were randomized into ASSCOPD, COPD, and control groups. ASSCOPD was further categorized into ASM and non-ASM groups. COPD model was established by combining fumigation with airway instillation of elastase; ASSCOPD model was developed based on COPD by induction with dry cold diet, cold dry environment, and plantar electric stimulation. ASM was administered twice daily. The pulmonary function was evaluated based on respiration. The mRNA and protein levels of AQPs were estimated by real-time PCR and Western blot, respectively. RESULTS: MV, TV, the mRNA level of AQP5, and the protein expression of AQP1, AQP4, and AQP5 were increased in ASMCOPD compared to ASSCOPD. CONCLUSION: The pulmonary function was impaired in ASSCOPD group; the expression of AQP1, AQP4, and AQP5 was decreased at protein and mRNA levels in ASSCOPD group. ASM can improve the pulmonary function in ASSCOPD for MV and TV. ASM could elevate the protein expression of AQP1, AQP4, and AQP5 and the mRNA level of AQP5 in lung tissue.

A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome).

OBJECTIVE: To evaluate the efficacy and safety of Yi Qi Gu Biao (YQGB) pill in treating frequent exacerbator phenotype in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome) (FEPCOPD). METHODS: This prospective, randomized, double-blind, controlled study assessed 112 cases (64 included) of FEPCOPD treated at the outpatient department in our hospital in January-August 2016. The patients were randomly divided into YQGB and placebo (Pb) and treated for three months. Lung function, CAT, mMRC, and TCM symptom scores (TCMs) were observed. RESULTS: Compared with Pb, YQGB showed decreased wheezing symptom scores (WSs) and TCMs at one month and decreased CAT and TCMs at three months. From one to three months, CAT, cough, sputum, WSs, and TCMs in YQGB were lower than pretreatment values. But in Pb, CAT was lower than pretreatment values after one month; CAT, sputum, and TCMs were lower than pretreatment values after two months; CAT, cough, sputum, WSs, and TCMs were lower than pretreatment values after three months. CONCLUSION: Yi Qi Gu Biao pill can improve wheezing, health status, and TCMs in FEPCOPD and also can shorten the durations of cough, sputum, and wheezing. This trial is registered in the Clinical Trials Registry of China: ChiCTR-IOR-15007542 (on 8 December 2015).

Clinical Study on Yiqi Gubiao Pill Combined with Pingchuan External Application Ointment for Treatment of Patients with Chronic Obstructive Pulmonary Disease at Stable Stage / 中国中医药信息杂志

Objective To observe efficacy and safety of Yiqi Gubiao Pill combined with Pingchuan External Application Ointment for the treatment of COPD (lung-spleen qi deficiency type) at a stable stage. Methods A randomized, double-blind, and placebo-controlled method was used. Totally 266 cases of patients diagnosed with COPD lung-spleen qi deficiency syndrome were randomly divided into four groups. Experimental Ⅰ group (72 cases) was given Yiqi Gubiao Pill, 10 pills each time, three times a day, orally; at the same time, experimental Ⅰ group was given simulated Pingchuan External Application Ointment (blank medical bag), for Feishu (BL13), danzhong (RN17), Pishu (BL20), Fengmen (BL12), and Dingchuan, external application at 11am each day, external heating stickers, 4-6 h each time, twice a week. Experimental Ⅱ group (64 cases) was given simulated Yiqi Gubiao Pill combined with Pingchuan External Application Ointment. Experimental (64 cases) was givenⅢ Yiqi Gubiao Pill combined with Pingchuan External Application Ointment. Control group (66 cases) was given simulated Yiqi Gubiao Pill combined with simulated Pingchuan External Application Ointment. The treatment lasted for three months, and the follow-up was three months. TCM symptom scores, FEV1%, FVC%, CAT, BODE index, mMRC, and 6MWT were observed. Results After three-month treatment and three-month follow-up, the improvement of TCM symptom scores of the 3 experimental groups was better than the control group (P<0.05). The improvement of CAT, mMRC, BODE index, 6MWT, mMRC in the three treatment groups were better than the control group (P<0.05). The improvement of mMRC and BODE in experimental Ⅰ and Ⅱ groups were better than those of experimental group (Ⅲ P<0.05). After three-month treatment, the improvement of FVC% in the three experimental groups was better than the control group (P<0.05). The improvement of FEV1% in the experimental Ⅱ and groups was better than the control groupⅢ(P<0.05). Conclusion Yiqi Gubiao Pill combined with Pingchuan External Application Ointment has obvious efficacy for the treatment of COPD with lung-spleen qi deficiency type.

Effects of Modified Zhisou Power on Epidermal Growth Factor Receptor and Neutrophil Elastase in Rats with Cold-Dryness Chronic Obstructive Pulmonary Disease / 中国中医药信息杂志

Objective To reveal the effects of cold-dryness and modified Zhisou Power on epidermal growth factor receptor (EGFR) and neutrophil elastase (NE) in rats with COPD. Methods COPD model was established with an elastase dose into the trachea combined with exposure to smoking for 90 d; cold-dryness COPD group was further developed by exposure to a cold, dry environment for 90 d. After 90 days, cold-dryness COPD rats was divided into cold-dryness group and Zhisou Power intervention group (treated with modified Zhisou Power for 7 days). On the 97th day, all rats were killed. Pathological changes in lungs were observed. mRNA and protein expression of EGFR were measured by RT-qPCR and Western blot, and the amount of NE in serum and BALF were examined by ELISA. Results EGFR mRNA and protein expression were significantly higher in COPD group, cold-dryness group and Zhisou Power intervention group than in control group. EGFR was significantly lower in Zhisou Power intervention group than in COPD group and cold-dryness group. NE was significantly higher in serum and BALF in COPD group, cold-dryness group and Zhisou Power intervention group than in control group. NE in BALF was significantly higher in cold-dryness group than in COPD group. NE in BALF was significantly lower in Zhisou Power intervention group than in cold-dryness group. Conclusion Modified Zhisou Power can down-regulate the expression of EGFR and the mount of NE in cold-dryness COPD rats to treat COPD.

Correlation of IL-17 gene polymorphism with chronic obstructive pulmonary disease in Xinjiang aera / 临床检验杂志

Objective To investigate the correlation of IL-17 gene polymorphism with chronic obstructive pulmonary diseases (COPD) in Xinjiang area.Methods Five single nucleotide polymorphism (SNP) loci of IL-17A gene,including rs2275913,rs3819024,rs3819025,rs4711998 and rs8193036,and 4 SNP loci of IL-17F gene such as rs12203582,rs1266828,rs7771466 and rs9382084 from 149 COPD patients and 97 healthy controls were performed typing using the multiple single-base extension SNP (SNaPshot) technology,and the risk correlations of different genotypes and alleles of these loci with COPD were analyzed.Results There was no difference in the SNP of 5 IL-17A gene loci and 4 IL-17A gene loci between stable COPD patients and healthy controls,and the mutation and genotype distribution of these loci were not correlated with COPD susceptibility.However,the linkage disequilibrium analysis showed that there was significant difference in the distribution of IL-17A gene haplotype CAA between COPD patients and healthy controls (OR =0.244,95％ CI:0.057-1.043,P ＜ 0.05).Conclusion The IL-17F and IL-17A gene polymorphisms are not correlated with the risk of COPD,but the haplotype CAA of 1L-17A gene may be related to the susceptibility of COPD in Xinjiang area.

Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window.

OBJECTIVE: To evaluate the efficacy and safety of the comprehensive interventions based on three Traditional Chinese medicine (TCM) patterns therapy in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and AECOPD risk window. METHODS: A prospective, multi-center, single-blinded, double-dummy and randomized controlled clinical trial is being conducted to test the therapeutic effects of a sequential two stage treatment. A total of 364 patients were enrolled into this study with 182 in each treatment group (TCM and conventional). Patients received medication (or control) according to their assigned group. TCM treatment according to syndrome differentiation for AECOPD were administered twice daily to patients with AECOPD over 7-21days, followed by TCM for AECOPD risk window (RW) over 28days. All patients were followed up for 6 months. Exacerbations were used as the primary outcome measures. Forced expiratory volume in the first second (FEV1) and the modified medical research council dyspnea (MMRC) scale, quality of life and mortality rate were used as secondary outcome measures. RESULTS: Of 364 randomized patients, 353 were included in the intention-to-treat analysis and 290 in the per-protocol analysis. In the TCM group, 16 patients (10.4%) reached the primary end point; 24 (17.7%) in the conventional group (RR 0.59, 95% CI 0.33-1.06; p=0.074). Among patients with a re-exacerbation, the median time to event was 107.5days (interquartile range [IQR], 39.5-129.0) in the TCM and 50days (IQR, 31-130.5) in the conventional group (P=0.011). After exacerbation therapy and a further 180-days follow-up, patients in the TCM group had significant improvements in dyspnea, as measured by MMRC (P=0.003), Patients in the TCM group also had improvements in health-related quality of life (P=0.002), as measured COPD Assessment Test (CAT). There was no difference between groups in death, and recovery of lung function. There were no differences between the TCM and conventional treatment group in adverse events. CONCLUSIONS: In patients presenting to the respiratory department with acute exacerbations of COPD, TCM treatments with syndrome differentiation will have beneficial effects with regard to re-exacerbation, relieving symptoms, improving quality of life for COPD patients.

Quality Assessment of Randomized Controlled Trials on Treatment of Chronic Obstructive Pulmonary Disease in Stationary Phase with Point Application / 中国中医药信息杂志

Objective To investigate the current situation of randomized controlled trials (RCTs) on the treatment of chronic obstructive pulmonary disease (COPD) in stationary phase with point application, and provide evidence for clinical practice. Methods Such databases as CNKI, VIP, and CBM were searched from the establishment date to October 2011 to collect the RCTs on the treatment of COPD in stationary phase with point application according to the predefined inclusion criteria. And the quality was assessed by using the Jadad scale, the revised CONSORT statement and other self-defined indexes. Results Among 32 included RCTs, 1 literature scored three points, 8 scored two points, 23 scored one point according to Jadad scale, and no RCT performed the allocation concealment. According to the CONSORT criteria, only one can be prompted randomized trials from the title of the article, 23 from abstracts, 2 literature showed how to determine the sample size, 7 described the method to generate random allocation sequence, only 1 literature mentioned blind method, 15 literature explicitly mentioned syndromes. Conclusion Currently, the methodology and reporting quality of studies on the treatment of COPD in stationary phase with point application are not good enough to provide reliable evidence for clinical practice, and we should improve the quality of our clinical research.

Randomized Controlled Trail of Pingchuan Cataplasm Combined with Hyperthermia Therapy for Stable Chronic Obstructive Pulmonary Disease with Qi Deficiency Syndrome of Both Lung and Spleen / 中国中医药信息杂志

Objective To investigate the clinical efficacy of Pingchuan cataplasm combined with hyperthermia therapy for stable chronic obstructive pulmonary disease (COPD) with qi deficiency syndrome of both lung and spleen. Methods Sixty patients of stable COPD with TCM syndrome of qi deficiency of both lung and spleen were selected and randomized into treatment group and control group, 30 cases in each group. Based on conventional treatment, the treatment group was treated by Pingchuan cataplasm combined with hyperthermia, and the control group was given analog stick applicator without additional heat treatment. After 6 weeks of treatment, the TCM symptom score and the time of the first exacerbation after treatment were observed. Results Compared with the control group, Pingchuan cataplasm can reduce the patients’ TCM symptom score (F=9.843, P=0.003), and extend the interval of acute exacerbation after treatment (F=4.451, P=0.040). Conclusion Pingchuan cataplasm combined with hyperthermia applicator can improve symptoms and reduce the frequency of acute exacerbation, thus can treat and prevent the acute exacerbation of COPD.

Effect of Acupoint Application Therapy on BODE Index and TCM Symptom Scores for COPD Patients in Stabilization Period of Lung-spleen Qi-deficiency Syndrome / 世界科学技术-中医药现代化

This study was aimed to investigate the effective on BODE index and traditional Chinese medicine (TCM) symptom scores with acupoint application therapy for patients of chronic obstructive pulmonary disease (COPD) in stabilization period of lung-spleen qi-deficiency syndrome. A total of 120 cases of inpatients and out-patients of the stable phase of COPD with TCM syndromes of lung-spleen qi-deficiency were selected. Conven-tional therapy was used in the treatment. All patients were divided into four groups, which are the hyperthermia plus acupoint application group, simple acupoint application group, simple hyperthermia group and blank control group. Each group contained 30 cases. All patients were given 6-week treatment. And the BODE index and TCM symptom scores were observed pre-treatment and post-treatment. The results showed that the BODE index was im-proved in the hyperthermia plus acupoint application group and the simple hyperthermia group. Symptoms of coughing, phlegm, wheezing, shortness of breath were reduced in all hyperthermia plus acupoint application group, simple acupoint application group and simple hyperthermia group. Symptoms of abdominal distention, spontaneous perspiration, easy to catch cold and cold sensation on the back were reduced in the group of hyperthermia plus acupoint application. Symptoms of spontaneous perspiration, easy to catch cold and cold sensation on the back can be improved in the group with simple hyperthermia. The symptom of spontaneous perspiration was improved in the group of simple acupoint application. It was concluded that acupuncture point application in combination with hy-perthermia therapy can significantly improve symptoms and quality of life, improve exercise tolerance in patients.

Effect of Family Pulmonary Rehabilitation Exercise on the Number of Acute Exacerbation of COPD / 世界科学技术-中医药现代化

This study was aimed to evaluate the number of acute exacerbation of chronic obstructive pulmonary disease (COPD) and quality of life with family pulmonary rehabilitation exercise. Randomized controlled method 584 was used in the study. The COPD patients in the stability drug treatment were divided into the treatment group and control group. The treatment group A was given health education and pulmonary rehabilitation training in the family. And the treatment group B was given health education and treatment of pulmonary rehabilitation training in the family with acupoint application therapy. Health education was given in the control group. Changes on the number of acute exacerbation of COPD and quality of life were observed. The intervention time was one year. The results showed that patients after one-year pulmonary rehabilitation exercise in the family, the acute exacerbation (AECOPD) times of treatment group A and group B were obviously decreased (P < 0.01) compared to pre-treatment. The OR value was (0.79, 2.02) and (0.59, 2.11), respectively. The quality of life of treatment group A and group B was obviously improved (P < 0.05). The OR value was (3.39, 10.11) and (4.23, 9.57), respectively. Compared to the control group, the quality of life in treatment group B was obviously improved (P < 0.05). The OR value was (0.59, 7.78). It was concluded that the pulmonary rehabilitation exercise in the family can decrease the number of AECOPD and improve the quality of life of patients, reduce the risk of COPD patients in the future. This method is worth popularizing in the clinical and community practice.

Study on Bronchial Asthma Patients with TNF-alpha-308 Gene Polymorphism and TCM Correlation between Han and Uyghur People in Xinjiang / 世界科学技术-中医药现代化

This study was aimed to investigate the distribution of tumor necrosis factor-alpha (TNF-alpha)-308 gene polymorphism and its correlation with asthma in TCM syndromes between Han and Uyghur People in Xin-jiang. The polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) method was applied in the detection of TNF-alpha-308 gene polymorphism among 160 bronchial asthma cases and 40 healthy con-trols. Traditional Chinese medicine (TCM) syndrome differentiation standard on bronchial asthma was applied in the syndrome differentiation of 160 bronchial asthma cases. And gene distributions of TCM syndrome differentia-tion were compared. The results showed that there was no significant difference between the genotypes (wild-type and mutant) and allele distribution between the asthma group and the normal control group, the Uyghur asthma group and Uyghur normal control group, the Han asthma group and Han normal control group, Uyghur normal control group and Han normal control group (P > 0.05). There was no significant difference on the TNF-alpha-308 genotype distribution among different TCM syndromes. There was no significant difference on TCM syndrome distribution between Han asthma patients and Uyghur asthma patients. It was concluded that bronchial asthma in Xinjiang may be nothing to do with ethnic group, TNF-alpha-308 gene polymorphism. And the bronchial asthma syndrome differentiation type may be nothing to do with the TNF-alpha-308 genotype distribution.

Clinical Evaluation of Xiaoqinglong Decoction for Acute Exacerbation of Chronic Obstructive Pulmonary Disease--A Systematic Review / 世界科学技术-中医药现代化

This study was aimed to assess the clinical evaluation of Xiaoqinglong decoction for acute exacerbation of chronic obstructive pulmonary disease (COPD). Literatures published before August 3rd, 2012 were searched in the database of CNKI, VIP, CBM and Wanfang Data to identify the randomized controlled trials (RCTs) and quasi-RCTs about Xiaoqinglong decoction for acute exacerbation of COPD in China. Literatures were screened ac-cording to the inclusive and exclusive criteria by two reviewers independently. And the methodology quality was evaluated after abstracting the data. Then, the RevMan 5.0 software was used for meta-analysis. Seventeen RCTs were included. Among 1173 patients, there were 608 cases in the clinical trial group and 565 in the control group. The meta-analysis showed that compared with western medicine (WM), the clinical effect of Xiaoqinglong decoction plus WM was significantly better [MD = 3.91, 95%CI (2.50, 6.12), P < 0.01]. The invasive ventilation plus Xiaoqinglong decoction was better than the invasive ventilation [MD = 3.48, 95%CI (1.45, 8.32), P =0.01]. The blood gas analysis showed that compared with WM, the PaO2 in the Xiaoqinglong decoction plus WM was significantly better [MD = 7.55, 95%CI (1.41, 13.68), P = 0.05]. There was statistical significance in PaCO2 of Xiaoqinglong decoction plus WM [MD = -7.11, 95%CI (-9.89, -4.33), P < 0.01]. Compared to the invasive ventilation, there was statistical significance in the invasive ventilation plus Xiaoqinglong decoction [MD = -6.66, 95%CI (-8.79, -4.54), P < 0.01]. For FEV1, compared with WM, Xiaoqinglong decoction plus WM was signifi-cantly better [MD = 6.97, 95%CI (3.60, 10.34), P < 0.01]. It was concluded that Xiaoqinglong decoction com-bined with WM methods can improve clinical efficacy of acute exacerbation of COPD in order to increase the clinical efficacy on a certain level.

Effects of Uygur Medicine Hyssopus Officinalis L. on Balance of Th1/Th2 and Th17/Treg of COPD Mice / 世界科学技术-中医药现代化

This article was aimed to study the Uygur medicine Hyssopus officinalis L. on the balance of Th1/Th2 and Th17/Treg of chronic obstructive pulmonary disease (COPD) mice in order to explore the mechanism of its treatment of COPD. The pre-fumigation method was copied to establish a mouse model of COPD. Mice were ran-domly divided into the normal control group, saline group and water extract of H. officinalis L. high, middle and low dose group. The level of serum IFN-λ, IL-4, IL-17 and IL-10 were detected with ELISA. The results showed that compared with the normal control group, the serum IL-4 and IL-17 level of the COPD model group were significantly higher (P < 0.05), and the serum IFN-λ and IL-10 level were significantly lower (P < 0.05). After drug intervention, the IL-4 and IL-17 level were significantly lower, and the IFN-λ and IL-10 level were significantly increased compared with the model group. The correlation analysis showed that the IFN-λ, IL-4, IL-17 and IL-10 were negatively related. It was concluded that H. officinalis L. played a certain role on correct-ing imbalances of Th1/Th2 and Th17/Treg.

Practice and Thinking on Operating Mechanism of National TCM Clinical Research Base in Xinjiang / 世界科学技术-中医药现代化

This article summed up experiences in construction of the national traditional Chinese medicine (TCM) clinical research base, elucidation of Xinjiang TCM clinical research base of experiences in building a full range of the protection of the operating mechanism, characteristics, effects, and good advice for a number of deficiencies in the management of the base.

Observation on Clinical Effect of Ping-Ai Granule I Treatment among 107 HIV/AIDS Infection Cases / 世界科学技术-中医药现代化

This study was aimed to observe the clinical effect of Ping-Ai GranulesⅠin the treatment of HIV/AIDS . A total of 107 AIDS cases were divided into Ping-Ai GranulesⅠgroup and Ping-Ai GranulesⅠunited with HAART group. The results showed that there was significant difference between Ping-Ai GranulesⅠgroup and Ping-Ai GranulesⅠunited with HAART group in aspects of symptoms, physical signs, Karnovsky Score and changes of CD4+ T lymphocyte . It was concluded that Ping-Ai GranulesⅠhad the function of improving patient's symptom and increasing patient's immunity and living quality .

Practical Experiences of Laboratory Platform Construction in the National Clinical Research Base of Traditional Chinese Medicine / 世界科学技术-中医药现代化

The establishment of the National Clinical Research Base of Traditional Chinese Medicine (TCM) is very helpful for TCM research. The construction of a Chinese medicine research laboratory is an important part of the National Clinical Research Base of TCM. In this paper, researches on Chinese medicine laboratory construc-tion were discussed. It was combined with the actual construction of research laboratories of our hospital. This ar-ticle also discussed the geographical features and clinical needs of the National Clinical Research Base of TCM construction. Ideas of laboratory plan, open laboratory and experimental shared services platform construction were put forward in advance .

Discussion on research method of TCM / 国际中医中药杂志

After several thousand years of development,TCM has formed its own sets of research methods.such as observation,comparison,classification,trial and error,and deduction,etc.Based on the unique TCM theory,experiences of clinical diagnosis and treatment of TCM,the author put forward that the research of TCM should combine macrophenomenon and microphenomenon,quality and quantity,and"Zheng"and"Xie",emphasize locality feature for the purpose of promoting the science research level.

Asthma morbidity and "stasis" relational research / 国际中医中药杂志

Methods Acute attack of asthma patients with 84 patients, divided into virtual Asthma Group, the other card-based group, another non-choice of 63 patients with asthma, as a control group. Detection of all selected in the peripheral blood TXA2; TPA, PAI; blood coagulation. Results ①asthma group and control group case-control study results: OR=2.950, 95% CI (1.504, 5.785) exposure risk of the disease as non-exposed group of 2.95 times. ②Asthma group and the control group between the various indicators of hemorheology, in addition to TPA (P＞0.05) no significant difference. Ms indicators are significant differences (P＜0.05), suggested that asthma in the blood change detection indicators relative to the control group have changed significantly. Conclusion ①"Stasis" and asthma-related, "Stasis" Asthma is a major cause of morbidity. ②From stasis treatment of asthma, Huoxue Huayu Prescription provide the basis for the treatment of asthma.